83 related articles for article (PubMed ID: 19733553)
1. Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast.
Easton N; Marshall FH; Marsden CA; Fone KC
Neuropharmacology; 2009 Dec; 57(7-8):653-64. PubMed ID: 19733553
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine produces changes in cortico-basal thalamic loop circuits: assessed by phMRI BOLD contrast.
Easton N; Marshall F; Fone K; Marsden C
Neuropharmacology; 2007 Mar; 52(3):812-26. PubMed ID: 17140608
[TBL] [Abstract][Full Text] [Related]
3. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain.
Easton N; Steward C; Marshall F; Fone K; Marsden C
Neuropharmacology; 2007 Feb; 52(2):405-14. PubMed ID: 17020775
[TBL] [Abstract][Full Text] [Related]
4. Region-specific effects of a tyrosine-free amino acid mixture on amphetamine-induced changes in BOLD fMRI signal in the rat brain.
Preece MA; Sibson NR; Raley JM; Blamire A; Styles P; Sharp T
Synapse; 2007 Nov; 61(11):925-32. PubMed ID: 17701967
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.
Alburges ME; Hoonakker AJ; Horner KA; Fleckenstein AE; Hanson GR
J Neurochem; 2011 May; 117(3):470-8. PubMed ID: 21323925
[TBL] [Abstract][Full Text] [Related]
6. Behavioural and pharmacological magnetic resonance imaging assessment of the effects of methylphenidate in a potential new rat model of attention deficit hyperactivity disorder.
Hewitt KN; Shah YB; Prior MJ; Morris PG; Hollis CP; Fone KC; Marsden CA
Psychopharmacology (Berl); 2005 Aug; 180(4):716-23. PubMed ID: 15864553
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain.
Chase TD; Carrey N; Brown RE; Wilkinson M
Brain Res Dev Brain Res; 2005 Apr; 156(1):1-12. PubMed ID: 15862622
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of the D- and L- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat.
Easton N; Marshall F; Fone KC; Marsden CA
Psychopharmacology (Berl); 2007 Jul; 193(1):11-30. PubMed ID: 17387459
[TBL] [Abstract][Full Text] [Related]
9. Effect of Thunbergia laurifolia, a Thai natural product used to treat drug addiction, on cerebral activity detected by functional magnetic resonance imaging in the rat.
Thongsaard W; Marsden CA; Morris P; Prior M; Shah YB
Psychopharmacology (Berl); 2005 Aug; 180(4):752-60. PubMed ID: 16001121
[TBL] [Abstract][Full Text] [Related]
10. Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile.
Segal DS; Kuczenski R
J Pharmacol Exp Ther; 1999 Oct; 291(1):19-30. PubMed ID: 10490882
[TBL] [Abstract][Full Text] [Related]
11. Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging.
Ireland MD; Lowe AS; Reavill C; James MF; Leslie RA; Williams SC
Neuroscience; 2005; 133(1):315-26. PubMed ID: 15893653
[TBL] [Abstract][Full Text] [Related]
12. Sensory-evoked potentials recordings from the ventral tegmental area, nucleus accumbens, prefrontal cortex, and caudate nucleus and locomotor activity are modulated in dose-response characteristics by methylphenidate.
Yang PB; Swann AC; Dafny N
Brain Res; 2006 Feb; 1073-1074():164-74. PubMed ID: 16473326
[TBL] [Abstract][Full Text] [Related]
13. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI.
Dixon AL; Prior M; Morris PM; Shah YB; Joseph MH; Young AM
Neuropharmacology; 2005 Feb; 48(2):236-45. PubMed ID: 15695162
[TBL] [Abstract][Full Text] [Related]
14. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI.
Chen YI; Choi JK; Jenkins BG
Synapse; 2005 Feb; 55(2):80-8. PubMed ID: 15529335
[TBL] [Abstract][Full Text] [Related]
15. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder.
Augustyniak PN; Kourrich S; Rezazadeh SM; Stewart J; Arvanitogiannis A
Behav Brain Res; 2006 Feb; 167(2):379-82. PubMed ID: 16246436
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic modulation of brain systems subserving decision making under uncertainty: a study with fMRI and methylphenidate challenge.
Schlösser RG; Nenadic I; Wagner G; Zysset S; Koch K; Sauer H
Synapse; 2009 May; 63(5):429-42. PubMed ID: 19184997
[TBL] [Abstract][Full Text] [Related]
17. Methylphenidate sensitization is prevented by prefrontal cortex lesion.
Lee MJ; Swann AC; Dafny N
Brain Res Bull; 2008 May; 76(1-2):131-40. PubMed ID: 18395622
[TBL] [Abstract][Full Text] [Related]
18. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.
Swanson CJ; Perry KW; Koch-Krueger S; Katner J; Svensson KA; Bymaster FP
Neuropharmacology; 2006 May; 50(6):755-60. PubMed ID: 16427661
[TBL] [Abstract][Full Text] [Related]
19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
20. Early stress and chronic methylphenidate cross-sensitize dopaminergic responses in the adolescent medial prefrontal cortex and nucleus accumbens.
Jezierski G; Zehle S; Bock J; Braun K; Gruss M
J Neurochem; 2007 Dec; 103(6):2234-44. PubMed ID: 17924950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
